Even though THC-abundant strains of marijuana are the most prevalent throughout North America, scientists have shown that the plant we have all come to love and respect has much more to offer than the oh-so familiar cannabinoid, delta-9-tetrahydrocannabinol. Strains with high levels of THC have dominated the market due to their strong euphoria-inducing effects, which is why most people are unfamiliar with the plethora of beneficial cannabinoids ripe with aptitude for medical application, too many to list in detail within this post.
Cannabidiol (CBD) is probably the most commonly known “secondary” cannabinoid among the active ingredients in marijuana, and has been heavily adopted for its medicinally therapeutic properties during the last couple years. CBD’s growing popularity due to its effectiveness has largely spurred public interest into the discovery and research of other cannabinoids ganja has to offer.
Cannabigerol (CBG) has been proven to provide relief from pain and depression with MORE effectiveness than tetrahydrocannabinol. CBG also differs from THC in that it does not interact with CB1 and CB2 receptors, but engages other receptors, such as the adrenoreceptors and serotonin receptors. It was first identified in 1964, but a high-yielding species was not cataloged until one was found in a French hemp field in the 1980s. Currently, the only known high-yielding strain rich in CBG resides in the greenhouses of GW Pharmaceuticals, the manufacturers of Sativex.
Don’t be fooled by the illusion of variety (medication wise, there is definitely a true variety in flavor) when your selection is plainly: indica, sativa, or hybrid, with options on potency. Stay apprised to where the medicinal marijuana industry is headed, and what it has to offer you as a patient, you may just find that the remedies other cannabinoids have to offer are a better fit for you than THC!